Dismay over decision: NO TSABRI FOR 1000 PATIENTS: BBC NEWS
Multiple sclerosis charities have said they are "bitterly disappointed" at a decision not to prescribe Tysabri in Scotland...But the Scottish Medicines Consortium said the economic case for the drug had not been demonstrated

SMC decisions are based on cost-effectiveness, using the cost per quality adjusted life year (QALY), which tries to determine the value of a treatment to a person's life, rather than the actual cost of providing the drug.

"Accountancy has trumped clinical evidence with this decision," Mr Jones added.

"For a well-defined group of people with MS, where the disease is running out of control, this drug is highly effective, leading to 60-70% reductions in relapses. Only an economist could make that sound expensive." MORE: BBC NEWS